Pricing Log in Create free account
Friday 6 November 2026 Export IOVA’s income statement to Excel — free account

Iovance Biotherapeutics, Inc.

IOVA Healthcare Biotechnology

Iovance Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $263.5 million, up 60.6% from fiscal 2024.

Revenue
+80.1%
EPS
+80.0%
Free cash flow
+89.7%

Quarter to September 2026, against a year earlier

7.99 0.25 +3.23%
Market cap
$3.5B
P/E
0.0×
Fwd P/E
−18.9×
Dividend yield
—
F-score
4/9
Altman Z
−2.30
Beneish M
−2.46
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Iovance Biotherapeutics, Inc. (IOVA) P/E ratio

Alert me on P/E ratio

Iovance Biotherapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
10 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
TNGX Tango Therapeutics, Inc. compare n/m
PBLS Parabilis Medicines, Inc. compare n/m
EWTX Edgewise Therapeutics, Inc. compare n/m
IRON Disc Medicine, Inc. compare n/m
ABCL AbCellera Biologics Inc. compare n/m
IOVA Iovance Biotherapeutics, Inc. n/m
RLAY Relay Therapeutics, Inc. compare n/m
XENE Xenon Pharmaceuticals Inc. compare n/m
ACAD ACADIA Pharmaceuticals Inc. compare 10.0×
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on IOVA